OSIVAX
  • COMPANY
    • ABOUT US
    • EXECUTIVE COMMITTEE
    • SCIENTIFIC ADVISORY BOARD
    • CLINICAL ADVISORY BOARD
    • BOARD OF DIRECTORS
    • PARTNERS
  • SCIENCE
  • PIPELINE
    • OVERVIEW
    • INFLUENZA - OVX836
    • CORONAVIRUS
  • NEWS
    • PRESS RELEASES
    • MEDIA COVERAGE
    • PUBLICATIONS
    • EVENTS
  • CONTACT
    • LEGAL MENTIONS

PIPELINE

OVERVIEW

Influenza - ovx836
oligoDOM® is a breakthrough cost-effective technology developed
  • Internally, at Osivax, in two indications: Flu and Immuno-oncology
  • In collaboration with public partners in other infectious diseases. The two most advanced programs are in Malaria with the Jenner Institute in the UK and Human Papilloma Virus (HPV) with the  DKFZ in Germany
Picture

legal mentions
contact us
Proudly powered by Weebly
  • COMPANY
    • ABOUT US
    • EXECUTIVE COMMITTEE
    • SCIENTIFIC ADVISORY BOARD
    • CLINICAL ADVISORY BOARD
    • BOARD OF DIRECTORS
    • PARTNERS
  • SCIENCE
  • PIPELINE
    • OVERVIEW
    • INFLUENZA - OVX836
    • CORONAVIRUS
  • NEWS
    • PRESS RELEASES
    • MEDIA COVERAGE
    • PUBLICATIONS
    • EVENTS
  • CONTACT
    • LEGAL MENTIONS